KAN-101 for Celiac Disease
(SynCeD Trial)
Trial Summary
What is the purpose of this trial?
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
Research Team
Study Director
Principal Investigator
Anokion SA
Eligibility Criteria
This trial is for people with Celiac Disease who have been on a gluten-free diet for at least a year. They should have certain genetic markers (HLA-DQ2.5), a previous diagnosis confirmed by tests, and specific biopsy results showing intestinal damage.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 3 intravenous (IV) infusions of KAN-101 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- KAN-101
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Lead Sponsor
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University